AI
Saturday, January 24, 2009 2:32:52 PM
UTHR:
Don't know if you noticed in the updated calendar but UTHR decided to amend the FREEDOM-M study so I guess we'll never know at my theory it had a better then average chance to show success (unless of course if fails
). A smart move IMO since the dose ranging study wouldn't be done for some time anyway and they likely would have need < .01 to get approval on just the M data. They are proposing to add 100 patients starting at the low dose titration (.25mg). Slides are available from JPM were they mention that at http://ir.unither.com/events.cfm
Do you (or anyone else) have a good link or data on the various efficacy rate of the Interferon's in MS (and Tysabri). Or is it better to not be lazy and just read the labels. TIA
Don't know if you noticed in the updated calendar but UTHR decided to amend the FREEDOM-M study so I guess we'll never know at my theory it had a better then average chance to show success (unless of course if fails
). A smart move IMO since the dose ranging study wouldn't be done for some time anyway and they likely would have need < .01 to get approval on just the M data. They are proposing to add 100 patients starting at the low dose titration (.25mg). Slides are available from JPM were they mention that at http://ir.unither.com/events.cfm Do you (or anyone else) have a good link or data on the various efficacy rate of the Interferon's in MS (and Tysabri). Or is it better to not be lazy and just read the labels
. TIA
Where Real Traders Talk Markets
Join thousands of traders sharing insights, catalysts, and charts.
